Ivosidenib Deemed Safe, Effective in AML
- PMID: 29934313
- DOI: 10.1158/2159-8290.CD-NB2018-082
Ivosidenib Deemed Safe, Effective in AML
Abstract
A phase I study suggests that ivosidenib can induce remission in patients with relapsed or refractory acute myeloid leukemia characterized by IDH1 mutations. The drug spurred complete remission or complete remission with partial hematologic recovery in 30.4% of patients. The most common side effects of at least grade 3 were prolonged QT interval and IDH differentiation syndrome.
©2018 American Association for Cancer Research.
Comment on
-
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.N Engl J Med. 2018 Jun 21;378(25):2386-2398. doi: 10.1056/NEJMoa1716984. Epub 2018 Jun 2. N Engl J Med. 2018. PMID: 29860938 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous